SVB Leerink analyst Joseph Schwartz said Solid Biosciences reported data for lead candidate SGT-001 that he views as "underwhelming" as he continue to believe that it is "just as important to consider the quality of microdystrophin that is expressed as it is to evaluate the quantity that is expressed." Despite Solid's optimism, the path forward for SGT-001 is unclear given the uncertainty of when, or if, the third clinical hold will be lifted, added Schwartz. However, he keeps an Outperform rating on Solid shares given his belief that there is value in the optimized transgene incorporated within SGT-001. He also sees the current valuation assuming the worst and thinks the stock could move higher if the clinical hold is lifted.